Published in Ann Neurol on January 01, 2006
Paraneoplastic syndromes of the CNS. Lancet Neurol (2008) 4.62
A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol (2014) 4.37
Antibodies and neuronal autoimmune disorders of the CNS. J Neurol (2009) 2.40
Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology (2008) 2.27
Autoimmune encephalopathies. Ann N Y Acad Sci (2014) 1.65
Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med (2010) 1.62
Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med (2013) 1.31
Neuroimaging insights into the pathophysiology of sleep disorders. Sleep (2008) 1.31
REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep (2012) 1.19
Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med (2006) 1.10
Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex. Neurologia (2014) 0.97
Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am (2006) 0.96
REM sleep behaviour disorder in older individuals: epidemiology, pathophysiology and management. Drugs Aging (2010) 0.93
Sleep loss as a factor to induce cellular and molecular inflammatory variations. Clin Dev Immunol (2013) 0.92
REM sleep behavior disorder and narcoleptic features in anti-Ma2-associated encephalitis. Sleep (2007) 0.85
Neuronal surface antibody-mediated autoimmune encephalitis. Semin Neurol (2014) 0.82
REM sleep behavior disorder in patients with guadeloupean parkinsonism, a tauopathy. Sleep (2007) 0.81
Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders. EPMA J (2011) 0.80
Morbidities in rapid eye movement sleep behavior disorder. Sleep Med (2013) 0.80
Rapid-eye-movement sleep behavior disorder secondary to acute aseptic limbic encephalitis. J Neurol (2009) 0.80
Rapid Eye Movement Sleep Behavior Disorder in Paraneoplastic Cerebellar Degeneration: Improvement with Immunotherapy. Sleep (2016) 0.77
Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in non-herpetic acute limbic encephalitis. J Neurol (2009) 0.77
Update on paraneoplastic neurologic disorders. Oncologist (2010) 0.77
Rapid eye movement sleep behavior disorder in adults younger than 50 years of age. Sleep Med (2013) 0.76
Autoimmune channelopathies of the nervous system. Curr Neuropharmacol (2011) 0.76
Rapid Eye Movement Sleep Abnormalities in Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). J Clin Sleep Med (2016) 0.75
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol (2013) 11.47
Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol (2010) 7.97
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain (2004) 7.38
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol (2011) 6.77
Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol (2009) 5.75
Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol (2006) 4.72
AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol (2009) 4.49
Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr (2012) 4.12
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Clinical analysis of anti-Ma2-associated encephalitis. Brain (2004) 3.89
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67
Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain (2008) 3.51
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 3.40
Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain (2013) 3.22
Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol (2012) 3.12
Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol (2011) 2.99
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain (2008) 2.91
Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain (2002) 2.77
Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol (2010) 2.54
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (2002) 2.48
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep (2005) 2.39
Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry (2013) 2.33
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology (2013) 2.32
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med (2007) 2.28
Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol (2009) 2.25
Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain (2006) 2.25
Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med (2010) 2.24
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry (2012) 2.15
Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol (2003) 2.05
N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol (2009) 2.03
Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol (2003) 2.02
Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol (2010) 1.99
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet (2013) 1.91
Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain (2011) 1.89
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol (2004) 1.89
Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science (2006) 1.88
Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol (2011) 1.82
Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol (2012) 1.80
Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol (2003) 1.69
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol (2012) 1.67
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain (2012) 1.65
CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica (2003) 1.62
Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys (2004) 1.62
Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J (2008) 1.61
Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys (2005) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology (2004) 1.56
Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis. J Neuroimmunol (2004) 1.56
N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord (2013) 1.55
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry (2013) 1.55
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clin Neurophysiol (2006) 1.54
Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res (2005) 1.53
Rapidly progressive diffuse Lewy body disease. Mov Disord (2011) 1.52
A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol (2013) 1.50
Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol (2010) 1.49
Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disord (2005) 1.47
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature (2007) 1.46
Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry (2012) 1.45
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
A candidate gene for autoimmune myasthenia gravis. Neurology (2012) 1.44
The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr (2012) 1.43
Diagnosis and the premotor phase of Parkinson disease. Neurology (2009) 1.42
[Provincial stroke code: characteristics and impact on health care]. Rev Neurol (2011) 1.40
Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol (2013) 1.40
Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res (2006) 1.39
Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (2010) 1.38
Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer (2003) 1.33
Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol (2008) 1.32
Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci (2003) 1.32
Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev Med Child Neurol (2011) 1.32
SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol (2009) 1.28
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol (2010) 1.28
Spectrum of paraneoplastic neurologic disorders in women with breast and gynecologic cancer. Medicine (Baltimore) (2003) 1.27
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol (2003) 1.24
Ion channels in genetic and acquired forms of epilepsy. J Physiol (2012) 1.24
Clinical neuropathology practice guide 5-2012: updated guideline for the diagnosis of antineuronal antibodies. Clin Neuropathol (2012) 1.23
Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia (2013) 1.22
Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol (2011) 1.21
NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol (2012) 1.21
Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J Neuroimmunol (2009) 1.20
Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Dev Med Child Neurol (2011) 1.20
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol (2005) 1.20
Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol (2005) 1.19